Septerna (NASDAQ:SEPN) Hits New 1-Year High – Here’s What Happened

Septerna, Inc. (NASDAQ:SEPN)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $29.43 and last traded at $28.4550, with a volume of 326676 shares traded. The stock had previously closed at $25.56.

Wall Street Analysts Forecast Growth

Several research analysts have commented on SEPN shares. HC Wainwright boosted their price objective on Septerna from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Wall Street Zen raised shares of Septerna from a “sell” rating to a “buy” rating in a report on Sunday, November 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of Septerna in a research note on Friday, September 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company raised shares of Septerna from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $18.00 to $28.00 in a report on Friday, November 14th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $27.67.

Septerna Trading Up 11.5%

The firm has a market capitalization of $1.28 billion and a PE ratio of -18.88. The business has a 50 day moving average price of $20.19 and a 200-day moving average price of $14.42.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%.The company had revenue of $21.50 million for the quarter, compared to analyst estimates of $24.50 million. On average, equities research analysts forecast that Septerna, Inc. will post -7.11 earnings per share for the current year.

Insiders Place Their Bets

In other Septerna news, SVP Daniel D. Long sold 3,501 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $18.06, for a total value of $63,228.06. Following the sale, the senior vice president owned 92,911 shares of the company’s stock, valued at approximately $1,677,972.66. This represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Septerna

A number of large investors have recently added to or reduced their stakes in SEPN. Russell Investments Group Ltd. purchased a new position in Septerna during the 3rd quarter valued at about $36,000. Covestor Ltd increased its stake in shares of Septerna by 55.8% during the 3rd quarter. Covestor Ltd now owns 3,620 shares of the company’s stock worth $68,000 after purchasing an additional 1,296 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Septerna by 88.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock worth $78,000 after purchasing an additional 1,945 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Septerna in the 1st quarter valued at approximately $49,000. Finally, JPMorgan Chase & Co. grew its holdings in Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after buying an additional 1,315 shares during the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.